– FDA authorization of IND for Phase 2 trial of EDP1815 in COVID-19 in the U.S.; data expected in 4Q 2020 ––Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in moderate psoriasis in the U.S., UK, and EU; trial initiation expected in 3Q 2020 with interim data expected by mid-2021––Additional data from Phase 1/2 trial of EDP1503 in TNBC expected in 4Q 2020––Up to 6 clinical readouts expected over next 6-12 months––Management to host conference call at 8:30 a.m. ET–
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today reported financial results and business highlights for the second quarter 2020.
“Our preclinical and clinical data support advancing our programs in psoriasis, COVID-19, atopic dermatitis, and triple-negative breast cancer (TNBC), with multiple clinical readouts expected over the next 6-12 months. In parallel, we continue to advance our preclinical programs in inflammation, oncology, neuroinflammation, and metabolism,” said Simba Gill, Ph.D., chief executive officer of Evelo. “Our recently completed follow-on offering provides the capital to pursue these clinical activities whilst continuing to explore additional opportunities to capture the therapeutic potential of SINTAX.”
Second Quarter 2020 Highlights and Recent Progress
EDP1815 in Moderate Psoriasis
-- Evelo has received regulatory and ethics authorization for its Phase 2 dose ranging trial at sites in the U.S., UK, and EU. The Company is on-track to initiate the trial in 3Q 2020. -- The trial will evaluate three doses of EDP1815 versus placebo in approximately 225 individuals with moderate psoriasis. The primary endpoint will be mean reduction in PASI score at 16 weeks.
EDP1815 in COVID-19
-- EDP1815 will be evaluated in two clinical trials for the treatment of hospitalized patients with COVID-19: a Phase 2 trial in partnership with Rutgers University and Robert Wood Johnson University Hospital, and TACTIC-E, a Phase 2/3 trial sponsored by the Cambridge University Hospitals NHS Foundation Trust and led by Addenbrooke’s Hospital in Cambridge, United Kingdom. -- The U.S. Food and Drug Administration (FDA) recently authorized the Company’s Investigational New Drug (IND) application for the Phase 2 trial in the U.S.
-- In July 2020, Evelo presented clinical data from its Phase 1/2 open-label study of EDP1503, in combination with pembrolizumab, at the ESMO World Congress on Gastrointestinal Cancer Virtual Meeting. -- The clinical trial included patients with advanced metastatic microsatellite stable colorectal carcinoma (MSS CRC), TNBC, and those with multiple tumor types who have relapsed on prior checkpoint inhibitor treatment. -- Preliminary data on 11 TNBC patients (8 on high dose and 3 on low dose EDP1503) was presented. The data showed an overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) across all TNBC patients receiving high dose EDP1503.
-- In June 2020, Evelo completed a public offering of 13.8 million shares of its common stock, including the underwriter’s option to purchase additional shares, at a public offering price of $3.75 per share, before underwriting discounts and commissions, raising approximately $52 million in gross proceeds. Additionally, in July 2020, Evelo drew down an additional $10 million under its existing loan and security agreement with K2HealthVentures. -- The U.S. Patent and Trademark Office has issued to Evelo U.S. Patent No. 10,702,561 entitled “Pharmaceutical compositions comprising a Blautia strain.” The patent relates to a pharmaceutical composition formulated for oral administration comprising a therapeutically effective amount of a Blautia strain. This is the second patent in this family.
Upcoming Key Milestones
-- Data from Phase 2 trial in COVID-19 in 4Q 2020 -- Interim safety data and futility analysis from Phase 2/3 TACTIC-E trial in 4Q 2020 -- Data from Phase 1b trial in atopic dermatitis in 1Q 2021 -- Interim data from Phase 2 trial in moderate psoriasis by mid-2021
-- Data from Phase 1b trial in atopic dermatitis in mid-2021
-- Additional data from Phase 1/2 trial in TNBC in 4Q 2020
Second Quarter 2020 Financial Results
-- Cash Position: As of June 30, 2020, cash and cash equivalents were $90.2 million, as compared to cash and cash equivalents of $77.8 million as of December 31, 2019. This increase was primarily due to $48.6 million in net proceeds received from the Company’s June 2020 follow-on underwritten public offering, partially offset by cash used in operating activities. Evelo now expects that its cash and cash equivalents, including the $10 million additional debt, will enable it to fund its planned operating expenses and capital expenditure requirements into the third quarter of 2021. -- Research and Development Expenses:R&D expenses were $15.2 million for the three months ended June 30, 2020, compared to $15.5 million for the three months ended June 30, 2019. The decrease of $0.3 million was primarily due to the impact of COVID-19, which delayed the trial initiation and patient recruitment across inflammation and oncology programs and reduced lab and external manufacturing activities, partially offset by continuous investment in R&D hiring and headcount growth. -- General and Administrative Expenses:G&A expenses were $5.1 million for the three months ended June 30, 2020, compared to $5.9 million for the three months ended June 30, 2019. The decrease of $0.8 million primarily reflects a $0.4 million decrease in lower travel and office expenditure due to the COVID-19 pandemic, and a $0.4 million decrease in personnel costs due to temporary lower G&A headcount. -- Net Loss:Net loss was $20.7 million for the three months ended June 30, 2020, or $(0.63) per basic and diluted share, as compared to a net loss of $20.9 million for the three months ended June 30, 2019, or $(0.65) per basic and diluted share.
Conference CallEvelo will host a conference call and webcast at 8:30 a.m. ET today. To access the call please dial (866) 795-3242 (domestic) or (409) 937-8909 (international) and refer to conference ID 7048016. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo BiosciencesEvelo Biosciences is a clinical stage biotechnology company developing oral biologics that act on SINTAX™, the small intestinal axis, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic and neurological systems. The company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19, and EDP1503 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements concerning the development of EDP1815 for the treatment of patients with COVID-19, our development plans, the promise and potential impact of any of our monoclonal microbials or preclinical or clinical trial data, the timing of and plans for clinical trials of EDP1815, EDP1867 and EDP1503, the timing and results of any clinical trials or readouts, and the sufficiency of cash to fund operations.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our operations, including our preclinical studies and clinical trials, and the continuity of our business; we have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in regulatory approval; our reliance on third parties and collaborators to expand our microbial library, conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; our lack of experience in manufacturing, selling, marketing, and distributing our product candidates; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; risks associated with international operations; our ability to retain key personnel and to manage our growth; the potential volatility of our common stock; our management and principal stockholders have the ability to control or significantly influence our business; costs and resources of operating as a public company; unfavorable or no analyst research or reports; and securities class action litigation against us.
These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Contact Jessica Cotrone, 978-760-5622 email@example.com
EVELO BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)(in thousands, except share and per share amounts)
Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Operating Expenses (1): Research and development $ 15,174 $ 15,464 $ 32,593 $ 31,141 General and administrative 5,071 5,923 10,913 11,050 Total operating expenses 20,245 21,387 43,506 42,191 Loss from operations (20,245 ) (21,387 ) (43,506 ) (42,191 ) Other income, net (318 ) 446 (33 ) 951 Loss before income taxes $ (20,563 ) $ (20,941 ) $ (43,539 ) $ (41,240 ) Income tax expense (89 ) — (154 ) — Net loss $ (20,652 ) $ (20,941 ) $ (43,693 ) $ (41,240 ) Net loss per share - basic and diluted $ (0.63 ) $ (0.65 ) $ (1.35 ) $ (1.29 ) Weighted-average common shares used in computing net 32,634,468 32,041,401 32,442,259 31,983,558 loss per share - basic and diluted --------- - --------- - --------- - --------- - (1) Expenses include the following amount of non-cash stock-based compensation expense: Research and development $ 1,083 $ 973 $ 2,149 $ 1,864 General and administrative 1,010 1,162 1,899 2,224
EVELO BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(in thousands)
June 30, 2020 December 31, 2019 Assets: Cash, cash equivalents $ 90,173 $ 77,833 Property and equipment, net 8,002 8,341 Right of use asset - operating lease 11,616 — Other assets 4,114 4,746 Total assets $ 113,905 $ 90,920 Liabilities and stockholders’ equity: Accounts payable, accrued expenses and other $ 11,820 $ 9,743 Long-term debt 19,806 19,634 Operating lease liability 12,770 — Other liabilities 303 1,346 Total liabilities 44,699 30,723 Total stockholders’ equity 69,206 60,197 Total liabilities and stockholders’ equity $ 113,905 $ 90,920 - ------- --- - ------ --------